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ABSTRACT
Objectives: To investigate the association between
repeated measures of affective symptoms collected
over 2 decades and hypertension (clinically ascertained
or self-report); to test whether, among people with
hypertension, affective symptoms are associated with
awareness of hypertension, and to evaluate the
longitudinal effects of the label of hypertension on
affective symptoms.
Methods: Multivariable logistic regression, accounting
for confounders and mediators, were used to test the
aforementioned associations in 1683 participants from
a national British cohort.
Results: Weak evidence of a cumulative impact of
affective symptoms across adulthood on self-reported
hypertension at age 60–64 years was observed (OR
1.40 (95% CI 1.10 to 1.78) and 1.19 (0.79 to 1.80) for
symptoms at 1–2 time points and at 3–4 time points
vs no symptoms, respectively). Study members with
affective symptoms in recent times were more likely to
have self-reported hypertension at age 60–64 years
than those without symptoms (OR 1.47 (1.10 to
1.96)). Similar results were observed for awareness of
hypertension (OR 2.00 (1.30 to 3.06)). Conversely, no
associations were found with clinically ascertained
hypertension. The act of labelling someone as
hypertensive at age 53 years was associated with
affective symptoms at age 60–64 years, independently
of antihypertensive treatment and affective symptoms
at the time of the diagnosis (OR 2.40 (1.32 to 4.36)).
Conclusions: Our findings suggest that elevated risk
of hypertension in participants with affective symptoms
might be explained by awareness of hypertension and
by exposure to medical attention, though not by a
direct effect of affective symptoms on blood pressure.
Conversely, long-term psychological consequences of
the label of hypertension are observed.
INTRODUCTION
The relationship between affective symptoms
and hypertension (HT), one of the most
important conventional risk factors for cardio-
vascular disease (CVD), has been studied for
nearly a century.1 Cross-sectional and longitu-
dinal studies report conﬂicting results: some
studies found positive associations between
mental distress and HT,2–6 whereas others
found null or even inverse associations.7–11
KEY QUESTIONS
What is already known about this subject?
▸ The relationship between symptoms of anxiety
and depression and hypertension (HT) has been
studied for nearly a century and cross-sectional
and longitudinal studies report conflicting
results. It is unclear whether patients with affect-
ive symptoms are more or less likely to be diag-
nosed and treated for HT. Some authors have
observed a tendency among clinicians to under-
diagnose HT in those with affective symptoms
(diagnostic overshadowing).
▸ Cross-sectional studies have demonstrated that
the act of labelling someone as hypertensive
may result in an increase in psychological dis-
tress by adopting a sick role, independently of
blood pressure values or antihypertensive treat-
ment status.
What does this study add?
▸ When considering the association between
affective symptoms and HT, potential misclassi-
fication due to self-report should be considered.
▸ This study showed that patients with affective
symptoms are more often diagnosed with HT
due to their increased access to healthcare.
▸ Awareness of HT is associated with affective
symptoms 10 years later after adjusting for
symptoms up until diagnosis.
How might this impact on clinical practice?
▸ Our findings suggest that long-term negative
psychological effects, as a consequence of the
label of HT, exist. Therefore, clinicians might
also consider appropriate positive health mes-
sages in patients with hypertension.
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Affective symptoms may be risk factors for HT
through the mediation of classic risk factors (smoking,
alcohol use and physical inactivity)12 or due to anti-
depressant treatment.9 Alternatively, HT may be a risk
factor for affective symptoms, as some studies have
demonstrated that the act of labelling someone as hyper-
tensive may result in an increase in psychological distress
by adopting a sick role, independently of blood pressure
(BP) values or antihypertensive treatment status.13–15
There are also contrasting views on whether those with
affective symptoms are more or less likely to be diag-
nosed and treated for HT. Some authors have observed
a tendency for clinicians to underdiagnose HT in those
with affective symptoms (diagnostic overshadowing)16;
others have shown that individuals with affective symp-
toms typically present to medical services more fre-
quently, potentially resulting in a rise of new HT
diagnoses.17
The inconsistent results observed in previous studies
might also be due to the different methods of assess-
ment of HT in epidemiological studies.18 Self-reporting
of HT is determined by respondents’ knowledge that
they have been diagnosed with HT, understanding of
the relevant information, ability to recall it, and willing-
ness to report it.19 As a consequence, when self-reported
data are the sole source of information on which HT is
classiﬁed, potential misclassiﬁcation may lead to bias in
the associations with risk factors.20
The aim of the present study is to investigate the asso-
ciation between repeated measures of affective symp-
toms collected over two decades and HT in late midlife
in a British community-based cohort, while accounting
for a large number of confounders and mediators. We
test the hypothesis that any association between affective
symptoms and HT is the same irrespective of the
method used to deﬁne HT (clinically ascertained or self-
report). We test whether, among people with HT, affect-
ive symptoms are associated with awareness of HT. We
also investigate whether awareness of HT impacts subse-
quent affective symptoms, while accounting for antihy-
pertensive treatment.
METHODS
Study members
The Medical Research Council National Survey of
Health and Development (NSHD) is a socially stratiﬁed
sample of 5362 singleton births that took place in
1 week of March 1946 in England, Scotland and Wales.21
Data collections in adult life were at 36, 43 and 53 years
when research nurses visited survey members in their
own homes. Between 2006 and 2010 (at 60–64 years),
2856 eligible study members were invited for an assess-
ment at one of six clinical research facilities (CRFs) or
to be visited by a research nurse at home.22 Of those
invited, 2229 (78%) were assessed: 1690 (59.2%)
attended a CRF and the remaining 539 were seen at
home. Of those not assessed at the CRF or at home
(n=627), 31 had died, 356 refused to participate and
240 completed only a postal questionnaire. Approval was
obtained from the Greater Manchester Local Research
Ethics Committee and the Scotland Research Ethics
Committee. Written informed consent was obtained
from all study members.
Assessment of BP and HT
At ages 53 and 60–64 years, BP was measured twice per
session by a trained nurse in the participant’s home or
at one of the CRFs.11 An average of two consecutive
readings was calculated. An automated digital oscillo-
metric sphygmomanometer (Omron HEM-705, Omron
Corp, Tokyo, Japan) was used. At each assessment, study
members were asked by research nurses on a clinic/
home visit whether they had taken any prescribed medi-
cations or tablets for high BP in the last year.
Antihypertensive medications included drugs listed in
the British National Formulary (BNF) in sections 2.2
(diuretics), 2.4 (β-blockers), 2.5 (HT and heart failure)
and 2.6.2 (calcium channel blockers).23 Clinically ascer-
tained HT was deﬁned according to the 2013 European
Society of Hypertension (ESH) and European Society of
Cardiology (ESC) guidelines for the management of
arterial HT as a mean systolic BP of 140 mm Hg or
higher, or as a mean diastolic BP of 90 mm Hg or
higher, or current use of antihypertensive medications.24
At the same occasions, information on HT status was
also collected on postal and clinic/home visit question-
naires. Then a further variable named self-reported HT
was determined by the answer to the following question
“Have you been told by a doctor that you have high BP
problems in the last 10 years”. As reported in other
studies,10 20 study members who responded with “yes” to
this question or declared their use of antihypertensive
medications were coded as having self-reported HT.
We deﬁned aware hypertensives as those with clinically
ascertained and self-reported HT, and unaware hyper-
tensive subjects as those with clinically ascertained but
no self-reported HT. Among those with clinically ascer-
tained and self-reported HT, based on antihypertensive
treatment, we further deﬁned aware treated hyperten-
sives and aware untreated hypertensives.
Assessments of affective symptoms
Details of assessments of symptoms of anxiety and
depression have been described previously.11 Brieﬂy, at
age 36 years, a short version of the Present State
Examination (PSE), a clinically validated interview admi-
nistrated by trained nurses, was used; the Index of
Deﬁnition (PSE-ID) provides a scale of severity ranging
from 1 to 7, with a threshold for caseness of 5 or more.
At age 43 years, the Psychiatric Symptom Frequency
(PSF) scale, an interview-based 23-item scale, was admi-
nistered with a validated threshold for potential caseness
between 22 and 23. At ages 53 and 60–64 years, study
members completed the 28-item self-administered
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General Health Questionnaire (GHQ-28), which corre-
lates highly with the PSE.11
Treatment with antidepressant medications was coded
at all these ages, and included any drug listed in the
BNF section 4.3 (tricyclic antidepressants, monoamine-
oxidase inhibitors, selective serotonin reuptake inhibi-
tors, and other antidepressant drugs).23
Covariates
Factors that could confound or mediate the main asso-
ciations were identiﬁed a priori. A full description of the
following covariates was extensively described else-
where.11 22 Data on smoking, drinking and physical
activity at ages 53 and 60–64 years as well as data on edu-
cational attainment by age 26 years and socioeconomic
position (SEP) at age 53 years were extracted from self-
completed questionnaires, nurse interviews and diet
diaries.
At age 53 and 60–64 years, body mass index (BMI)
was calculated as weight in kilograms divided by height
in metres squared. Heart rate was measured by the auto-
mated digital oscillometric sphygmomanometer cited
above. Diabetes mellitus was a self-reported diagnosis
conﬁrmed by general practitioners, or a fasting blood
glucose concentration of at least 7.0 mmol/L, or gly-
cated haemoglobin of at least 6.5%, or use of insulin or
oral antidiabetic agents. History of CVD included non-
fatal myocardial infarction, acute coronary syndrome,
surgical and percutaneous coronary revascularisation,
angina pectoris, chronic ischaemic heart disease, stroke
and heart failure.
Statistical methods
We used χ2 and Student t tests to examine differences in
characteristics of study members by clinically ascertained
and self-reported HT status at age 60–64 years and,
among hypertensives, by awareness HT status.
We created two lifetime affective caseness variables: a
cumulative variable based on the number of times an
individual was classiﬁed as a ‘case’ during the follow-up
(no symptoms, case-level symptoms at 1–2 time points
and case-level symptoms at 3–4 time points) and an age-
speciﬁc variable based on the speciﬁc timing an individ-
ual was classiﬁed as a ‘case’ during the follow-up (no
symptoms, case-level symptoms only in the past (age 36
and/or 43 and/or 53 years) and case-level symptoms in
recent times). We ﬁrst test the hypothesis that any associ-
ation between affective symptoms and HT is the same
irrespective of the method used to deﬁne HT.
Multivariable logistic regression models were used to
compute ORs with 95% CIs of being a clinically ascer-
tained HT case, and separately a self-reported HT case at
age 60–64 years by lifetime affective caseness variables
(cumulative and age-speciﬁc), initially unadjusted
(model 1) and then adjusted for the confounders,
gender, BMI at age 60–64 years, educational attainment,
SEP, and history of CVD and diabetes mellitus at age
60–64 years (model 2). Further adjustments were then
made for the potential mediators’ heart rate, smoking
status, drinking status, physical activity and antidepres-
sant treatment at age 60–64 years (model 3).
Using multivariate logistic regressions adjusted for the
covariates aforementioned, we tested whether, among
people with HT, affective symptoms are associated with
awareness of HT (aware vs unaware hypertensives) at
age 60–64 years. We additionally adjusted for duration of
clinically ascertained HT in years (model 4).
Finally, to investigate possible causal direction (aware-
ness of HT preceding development of affective symp-
toms), we tested the association between awareness of
HT at age 53 years and affective symptoms at age 60–
64 years, with adjustments for affective symptoms at age
53 years to account for existing symptoms, gender and
other covariates at age 53 years (namely BMI, SEP,
history of CVD and diabetes mellitus, heart rate,
smoking and drinking status, physical activity and antihy-
pertensive treatment). This analysis is based on 1619
study members with available data on BP and other cov-
ariates at age 53 years and affective symptoms at age 60–
64 years. To further investigate the potential impact of
the antihypertensive treatment, we created at age
53 years an awareness HT status by an antihypertensive
treatment variable: unaware hypertensives (reference),
aware treated hypertensives and aware untreated hyper-
tensives. We then tested the association between this
variable and affective symptoms at age 60–64 years with
adjustments for the same covariates as above.
Analyses were repeated (1) in study members with
incomplete data on affective symptoms across adulthood
and complete case information on all variables included
up to model 4 (sex, BMI at age 60–64 years, education,
SEP at age 53 years, history of CVD and diabetes mellitus
at age 60–64 years) to maximise the sample size (n=1905);
(2) considering a greater level of severity of HT (systolic
BP of 160 mmHg or higher, or as diastolic BP of
95 mm Hg or higher) and (3) considering awareness of
HT in controlled and uncontrolled treated hypertensives.
The analyses presented, unless otherwise speciﬁed, are
based on the sample with complete data on affective
symptoms at all four ages, all covariates and at least one
of the outcome measures (n=1683). Analyses were con-
ducted using SAS software, V.9.3 (SAS Institute, Cary,
North Carolina, USA).
RESULTS
Characteristics of participants
The ﬂow chart of the 1683 study members at age 60–
64 years by HT status (clinically ascertained and self-
reported) is illustrated in ﬁgure 1. The prevalence of
clinically ascertained and self-reported HT was 58.3%
and 41.7%, respectively. Two-thirds of the study
members with HT (66.1%) were aware of HT (ie, with
both clinically ascertained and self-reported HT) and
one-third (33.9%) were unaware of it (ie, with HT but
no self-reported HT). Only 7.6% self-reported HT while
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they had a normal BP value and were not on antihyper-
tensive treatment. The percentage of study members
with self-reported HT based only on the questionnaire
on antihypertensive medication was 9.5% (n=67), 53 of
whom were also assigned to the clinically ascertained
HT group. Among the 562 treated hypertensives, 51.6%
had normalised BP (systolic BP<140 mm Hg and dia-
stolic BP<90 mm Hg). Among the 420 untreated hyper-
tensives, only 20.7% self-reported that they had high BP
(aware untreated hypertensives).
Table 1 summarises the general characteristics of the
1683 study members (52.4% women) at age 60–64 years
by clinically ascertained and self-reported HT status.
Affective symptoms and clinically ascertained and
self-reported HT at age 60–64 years
When we considered the association between the cumu-
lative lifetime affective variable and self-reported HT
(table 2), in the unadjusted analysis study members
reporting affective symptoms at 1–2 time points and at
3–4 time points were more likely to have self-reported
HT than those without symptoms (p value for trend
0.001). In the fully adjusted model, the association in
those with affective symptoms at 3–4 time points was
considerably attenuated, providing little evidence of a
cumulative impact of affective symptoms across adult-
hood on self-reported HT at age 60–64 years (p value
for deviation from linear trend 0.08).
There was evidence of an association between the age-
speciﬁc lifetime affective variable and self-reported HT
(table 2). Study members with affective symptoms only
in the past and those with symptoms in recent times
were more likely to have self-reported HT than those
without symptoms, with the OR for those with symptoms
in recent times being greater (p value for heterogeneity
across groups 0.02). There was no evidence of associa-
tions between cumulative and age-speciﬁc lifetime affect-
ive variables and clinically ascertained HT (table 2).
Case-level affective symptoms at each of ages 36, 43, 53
and 60–64 years were not associated with odds of clinic-
ally ascertained HT at ages 60–64 years at all levels of
covariate adjustment (see online supplementary
table S1). In contrast, in the fully adjusted model, only
those with case-level affective symptoms at 60–64 years
had greater odds of self-reported HT at the same age
(OR 1.38; 95% CI 1.04 to 1.81) (see online supplemen-
tary table S2).
Affective symptoms and awareness of HT at ages 60–64
years
Aware hypertensives at ages 60–64 years (n=649) com-
pared with those unaware (n=333) were more likely to
be female, to have lower systolic BP and diastolic BP, to
have higher BMI, to be physically inactive, to have a
higher prevalence of diabetes mellitus, history of CVD,
affective symptoms at ages 60–64 years, to be treated
with antidepressants and antihypertensive drugs and to
be hypertensives at age 53 years than those unaware (see
online supplementary table S3).
When we considered the association between the
cumulative lifetime affective variable and awareness of
HT (table 3), in unadjusted analyses study members
reporting affective symptoms at 1–2 time points and at
3–4 time points were more likely to be aware of HT than
those without symptoms. In the fully adjusted model, the
association in those with affective symptoms at 3–4 time
points was considerably attenuated, providing little evi-
dence of a cumulative impact of affective symptoms
across adulthood on awareness of HT at age 60–64 years.
There was evidence of an association between the age-
speciﬁc lifetime affective variable and awareness of HT
(table 3). In unadjusted models, study members with
affective symptoms only in the past and those with symp-
toms in recent times were more likely to be aware of HT
at age 60–64 years than those without symptoms, with
the OR for those with symptoms in recent times being
greater (p value for heterogeneity across groups
Figure 1 Flow chart of the 1683 study members at age 60–
64 years by hypertension (HT) status. Clinically ascertained
HT is based on the European Society of Hypertension (ESH)/
European Society of Cardiology (ESC) 2013 guidelines
(normotensives are patients with systolic blood pressure
(SBP) <140 and diastolic blood pressure (DBP) <90 mm Hg
and no medication use). Self-reported HT is based on
self-completed questionnaires (normotensives are patients
with negative reply on the question about HT knowledge and
negative reply on question on medication use).
4 Tikhonoff V, Hardy R, Deanfield J, et al. Open Heart 2016;2:e000341. doi:10.1136/openhrt-2015-000341
Open Heart
Table 1 Characteristics of the study participants at age 60–64 years by clinically ascertained and self-reported HT (n=1683)
Clinically ascertained HT* Self-reported HT†
All participants
(n=1683)
Normotensive
(n=701)
Hypertensive
(n=982) p Value
Normotensive
(n=981)
Hypertensive
(n=702) p Value
Characteristics
Clinically ascertained HT, n (%)* 982 (58.3) – – – 333 (33.9) 649 (92.4) <0.0001
Self-reported HT, n (%)† 702 (41.7) 53 (7.6) 649 (66.1) <0.0001 – – –
Gender (women), n % 883 (52.4) 417 (59.5) 466 (47.5) <0.0001 527 (53.7) 356 (50.7) 0.22
Clinical features
SBP (mm Hg)‡ 136.2±18.0 124.1±0.6 144.9±0.5 <0.0001 133.0±0.7 140.6±0.6 <0.0001
Diastolic blood pressure (mm Hg)‡ 77.8±9.8 72.9±0.3 81.9±0.3 <0.0001 76.6±0.3 79.5±0.4 <0.0001
Heart rate (bpm) 68.6±11.0 67.8±0.4 69.2±0.3 0.009 68.4±0.4 68.9±0.4 0.42
Body mass index (kg/m2)§ 28.0±4.9 26.4±0.2 29.1±0.2 <0.0001 27.0±0.1 29.4±0.2 <0.0001
Questionnaire data
Educational achievement at age
26 years (higher level), n (%)
682 (40.5) 309 (44.1) 373 (37.9) 0.01 412 (42.0) 270 (38.5) 0.14
SEP at age 53 years (non-manual
skill), n (%)
1134 (67.4) 487 (69.5) 647 (65.9) 0.12 687 (70.0) 447 (63.7) 0.006
Smokers (current), n (%) 190 (11.3) 80 (11.4) 110 (11.2) 0.89 106 (10.8) 84 (12.0) 0.46
Drinkers (≥5 g/day), n (%) 1067 (63.4) 537 (76.6) 707 (72.0) 0.03 747 (76.2) 497 (70.8) 0.014
Leisure time physical activity
(inactive), n (%)
1059 (63.0) 414 (59.1) 645 (65.7) 0.006 590 (60.1) 469 (66.8) 0.005
Antihypertensive treatment, n (%) 562 (33.4) 0 (0.0) 562 (57.2) – 0 (0.0) 562 (80.1) –
Diabetes mellitus, n (%) 164 (9.7) 29 (4.1) 135 (13.7) <0.0001 47 (4.8) 117 (16.7) <0.0001
History of CVD, n (%) 212 (12.6) 42 (6.0) 170 (17.3) <0.0001 66 (6.7) 146 (20.8) <0.0001
Affective symptoms, n (%)¶ 298 (17.7) 119 (17.0) 179 (18.2) 0.51 149 (15.2) 149 (21.2) 0.001
Antidepressant treatment, n (%) 130 (7.7) 58 (8.3) 72 (7.3) 0.47 69 (7.0) 61 (8.7) 0.20
Values are arithmetic means±SE or number of participants (%).
*Clinically ascertained HT=definition based on the ESH/ESC 2013 guidelines (normotensives are patients with SBP<140 and DBP<90 mm Hg and no medication use).
†Self-reported HT=definition based on the questionnaire (normotensives are patients with a negative reply on the question about HT knowledge and a negative reply on the question on
medication use).
‡Average of two blood pressure readings.
§The body mass index is weight in kilograms divided by the square of the height in metres.
¶Total GHQ-28 score ≥5.
CVD, cardiovascular disease; DBP, diastolic blood pressure; ESC, European Society of Cardiology; ESH, European Society of Hypertension; GHQ-28, General Health Questionnaire–28-items;
HT, hypertension; SBP, systolic blood pressure; SEP, socioeconomic position.
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Table 2 Logistic regression between clinically ascertained and self-reported HT at age 60–64 years and lifetime affective caseness variables (n=1683)
Clinically ascertained HT vs normotension (982 vs 701)
Cumulative lifetime affective caseness (OR (95% CI))* Age-specific lifetime affective caseness (OR (95% CI))*
No
symptoms
(n=1080)
Case-level symptoms
at 1–2 time points
(n=474)
Case-level symptoms
at 3–4 time points
(n=129)
p
Value†
No
symptoms
(n=1080)
Case-level symptoms
only in the past
(n=305)
Case-level symptoms
in recent times (n=298)
p
Value†
Model 1 1.00 0.99 (0.79 to 1.23) 1.10 (0.76 to 1.59) 0.87 1.00 0.95 (0.74 to 1.23) 1.08 (0.83 to 1.40) 0.75
Model 2 1.00 0.98 (0.77 to 1.24) 0.98 (0.64 to 1.47) 0.83 1.00 0.93 (0.70 to 1.22) 1.04 (0.78 to 1.38) 0.79
Model 3 1.00 1.01 (0.79 to 1.28) 1.01 (0.66 to 1.54) 0.84 1.00 0.95 (0.72 to 1.26) 1.07 (0.80 to 1.43) 0.80
Self-reported HT vs normotension (702 vs 981)
Model 1 1.00 1.44 (1.16 to 1.80) 1.48 (1.03 to 2.14) 0.001 1.00 1.32 (1.02 to 1.71) 1.60 (1.24 to 2.07) 0.0006
Model 2 1.00 1.41 (1.11 to 1.78) 1.22 (0.81 to 1.83) 0.004 1.00 1.27 (0.96 to 1.67) 1.48 (1.12 to 1.97) 0.01
Model 3 1.00 1.40 (1.10 to 1.78) 1.19 (0.79 to 1.80) 0.02 1.00 1.26 (0.95 to 1.67) 1.47 (1.10 to 1.96) 0.02
Model 1: unadjusted logistic regression.
Model 2: logistic regression adjusted for gender, BMI at age 60–64 years, educational attainment by age 26 years, socioeconomic position at age 53 years, history of CVD and diabetes mellitus
status at age 60–64 years.
Model 3: model 2 additionally adjusted for covariates at age 60–64 years: heart rate, current smoking, alcohol consumption, physical activity and antidepressant treatment.
*Affective caseness assessed at each time point as follow: PSE-ID≥5 at age 36 years, total PSF score ≥23 at age 43 years, and total GHQ-28 score ≥5 at ages 53 and 60–64 years.
†p Value for trend.
BMI, body mass index; CVD, cardiovascular disease; GHQ-28, General Health Questionnaire–28-items; HT, hypertension; PSE-ID, Present State Examination-Index of Definition; PSF,
Psychiatric Symptom Frequency.
Table 3 Logistic regression between awareness of hypertension at age 60–64 years and lifetime affective caseness variables (n=982)
Aware vs unaware hypertensives (649 vs 333)
Cumulative lifetime affective caseness (OR (95% CI))* Age-specific lifetime affective caseness (OR (95% CI))*
No
symptoms
(n=629)
Case-level symptoms
at 1–2 time points
(n=275)
Case-level symptoms
at 3–4 time points
(n=78)
p
Value†
No
symptoms
(n=629)
Case-level symptoms
only in the past
(n=174)
Case-level symptoms
at recent time (n=179)
p
Value†
Model 1 1.00 2.20 (1.60 to 3.05) 1.78 (1.05 to 3.00) <0.0001 1.00 1.94 (1.33 to 2.82) 2.28 (1.55 to 3.55) <0.0001
Model 2 1.00 1.97 (1.40 to 2.76) 1.45 (0.83 to 2.52) 0.003 1.00 1.72 (1.16 to 2.55) 1.93 (1.32 to 2.96) 0.0005
Model 3 1.00 1.90 (1.34 to 2.67) 1.34 (0.76 to 2.36) 0.001 1.00 1.66 (1.11 to 2.48) 1.87 (1.24 to 2.82) 0.002
Model 4 1.00 1.91 (1.34 to 2.72) 1.55 (0.86 to 2.78) 0.001 1.00 1.67 (1.10 to 2.53) 2.00 (1.30 to 3.06) 0.001
Aware hypertensives=patients with both clinically ascertained and self-reported hypertension.
Unaware hypertensives=patients with clinically ascertained hypertension but not self-reported hypertension.
Model 1: unadjusted logistic regression.
Model 2: logistic regression adjusted for gender, body mass index (BMI) at age 60–64 years, educational attainment by age 26 years, socioeconomic position at age 53 years, history of
cardiovascular disease (CVD) and diabetes mellitus status at age 60–64 years.
Model 3: model 2 additionally adjusted for covariates at age 60–64 years: heart rate, current smoking, alcohol consumption, physical activity and antidepressant treatment.
Model 4: model 3 additionally adjusted for duration of clinically ascertained hypertension in years from age 36 years.
*Affective caseness assessed at each time point as follow: Present State Examination-Index of Definition (PSE-ID) ≥5 at age 36, total Psychiatric Symptom Frequency (PSF) score ≥23 at age
43, and total General Health Questionnaire–28-items (GHQ-28) score ≥5 at ages 53 and 60–64 years.
†p Value for trend.
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<0.0001). These results were similar after adjustment for
lifestyle behaviours and antidepressant medication at
age 60–64 years (model 3). The additional adjustment
for duration of clinically ascertained HT strengthened
the association (model 4).
Awareness of HT at age 53 years and affective symptoms
at age 60–64 years
The prevalence of clinically ascertained HT at age
53 years was 45.7% (n=769) and 39.0% (n=300) were
aware of HT (see online supplementary table S3). No
differences on systolic and diastolic BP, and antidepres-
sant treatment were observed by awareness HT status at
age 53 years, while aware hypertensives were more likely
to have a lower heart rate and lower educational level
and adult SEP, and to be non-smokers, non-drinkers and
physically active than those unaware.
When we considered the association between aware-
ness of HT at age 53 years and affective symptoms at age
60–64 years adjusted for gender, affective symptoms and
other covariates at age 53 years, aware hypertensives
were more likely to have affective symptoms at age 60–
64 years than those unaware (OR 1.90, 95% CI 1.24 to
2.91; p=0.002). These results were similar after adjust-
ment for antihypertensive treatment at age 53 years (OR
2.40, 95% CI 1.32 to 4.36; p=0.004).
In unadjusted and fully adjusted models, both aware
treated hypertensives and aware untreated hypertensives
at age 53 years were more likely to have affective symp-
toms at age 60–64 years than those unaware (table 4).
Sensitivity analysis
In the larger sample of 1905 study members, we con-
ﬁrmed the fully adjusted ﬁndings of table 2 (case-level
symptoms at 1–2 time points OR 1.38, 95% CI 1.11 to
1.72 and case-level symptoms at 3–4 time points OR
1.17, 95% CI 0.79 to 1.72; p value for trend 0.02; and
case-level symptoms only in the past OR 1.21, 95% CI
0.94 to 1.57 and case-level symptoms in recent times OR
1.49, 95% CI 1.14 to 1.96; p value for trend 0.01).
Analyses using the higher cut-off values for the diagno-
sis of HT resulted in similar but weaker ﬁndings than
those from table 3 (see online supplementary table S4).
Analysis considering BP control achievement at age
53 years in patients with hypertension resulted in similar
ﬁndings than those from table 4 (see online supplemen-
tary table S5).
DISCUSSION
In a nationally representative British sample, for the
ﬁrst time evidence was found for an association between
awareness of HT at age 53 years and affective symptoms
10 years later after adjustment for symptoms up until
diagnosis, which suggests a causal association from diag-
nosis to symptoms. This association was independent of
antihypertensive treatment. Conversely, an association
was observed between affective symptoms and self-
reported HT at age 60–64 years, while no association was
found with clinically ascertained HT. Affective symptoms
in recent times were strongly associated with self-
reported HT at age 60–64 years, while the cumulative
impact of affective symptoms across adulthood was weak.
The association, robust to adjustment for a wide range
of potential confounders, was not explained by lifestyle
behaviours or use of antidepressant medication. Finally,
an association was also observed between the presence
of affective symptoms in recent times and awareness of
HT at age 60–64 years. Duration of clinically ascertained
HT did not inﬂuence this association.
As illustrated in ﬁgure 2, the association observed
among people aware of their HT status may reﬂect the
impact of having an HT diagnosis on affective symptoms,
termed the labelling effect. Cross-sectional studies have
demonstrated higher psychological distress and lower
well-being in labelled hypertensives and mislabelled nor-
motensives in comparison with unaware hypertensives.13
Being labelled as hypertensive, whether or not indivi-
duals are treated, or whether BP is within normal range
(ie, mislabelled normotensives) or high, is associated
Table 4 Logistic regression between affective symptoms at age 60–64 years and awareness of HT at age 53 years (n=755)
Case of affective symptoms at age 60–64 years vs non-case (127 vs 628)*
Awareness of HT at age 53 years by antihypertensive treatment status (OR (95% CI))
Predictor Unaware (n=460) Aware treated (n=212) Aware untreated (n=83) p Value†
Model 1 1.00 2.33 (1.53 to 3.56) 2.49 (1.41 to 4.41) <0.0001
Model 2 1.00 1.86 (1.71 to 2.97) 2.40 (1.34 to 4.29) 0.003
Model 3 1.00 1.69 (1.04 to 2.74) 2.40 (1.32 to 4.36) 0.007
Unaware hypertensives=patients with clinically ascertained but not self-reported HT.
Aware treated hypertensives=patients with antihypertensive treatment with both clinically ascertained and self-reported HT.
Aware untreated hypertensives=patients without antihypertensive treatment with both clinically ascertained and self-reported HT.
Model 1: unadjusted logistic regression.
Model 2: logistic regression adjusted for gender, BMI at age 53 years, educational attainment by age 26 years, socioeconomic position at age
53 years and the following covariates at age 53 years: history of CVD and diabetes mellitus status, heart rate and lifestyle behaviours.
Model 3: model 2 additionally adjusted for affective symptoms at age 53 years.
*Affective caseness assessed as total GHQ-28 score ≥5.
†p Value for trend.
BMI, body mass index; CVD, cardiovascular disease; GHQ-28, General Health Questionnaire–28-items; HT, hypertension.
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with similar adverse responses.25 Only one prospective
study reported that a greater number of newly treated
hypertensives reported increased awareness of symptoms
by 6-month follow-up.26
Our ﬁndings also suggest that the association between
affective symptoms and HT seems to be explained by
study members’ knowledge and understanding of HT
itself rather than elevated BP. Indeed, the association
between affective symptoms across adulthood and sys-
tolic BP in early old age is actually an inverse one in this
cohort.11 Those with affective symptoms may be more
likely to seek medical advice and thus be diagnosed with
HT (ﬁgure 2). In this respect, Robinson27 found that
patients who consulted a doctor and were diagnosed as
hypertensive did not differ in depression scores from
those diagnosed as normotensive, but both groups were
more depressed than individuals who did not consult a
doctor.
Finally, our results suggest that the method of ascer-
tainment of HT is of paramount importance. Previous
studies based on self-reported HT have generally found
a positive association with depression;3–4 6 28 whereas
studies based on clinically ascertained HT reported no
association with depression.7–9 29 In a meta-analysis that
included 83 studies on BP and personality, Jorgensen
et al30 found an association between high BP and nega-
tive affect when individuals were aware of their BP levels,
but a reverse association when they were unaware.30 The
few prior studies with both HT deﬁnitions available
found that affective symptoms were associated with self-
reported HT, but not with actual elevation in BP.17 18
Strengths and limitations of this study
The main strength of this study is the longitudinal col-
lection of information on affective symptoms and on
both clinically ascertained and self-reported HT across
adulthood in a nationally representative cohort. This
allowed us to study the relationship between lifetime
affective symptoms and HT taking into account the
method used to deﬁne HT, and also to investigate for
the ﬁrst time a possible causal direction in the associ-
ation (awareness of HT preceding development of
affective symptoms). The importance of repeated assess-
ments when evaluating the effect of mental distress on
HT has been emphasised, because of the ﬂuctuation of
affective symptoms over time.5 The increasing number
of assessments provides a more precise exposure
measure.
Study limitations include the use of different measures
of affective caseness over time. However, each measure
has its own validated threshold for case-level symptoms.
The reliance on two BP measurements taken during a
single physical examination instead of multiple measure-
ments over longer time intervals may have led to biased
estimates of clinically ascertained HT prevalence. The
presence of white coat HT may induce an overestimation
of the prevalence of clinically ascertained HT and a con-
comitant underestimate of the prevalence of self-
reported HT.20 However, this should have strengthened
the association with clinically ascertained HT, if any-
thing. Different antihypertensive drug classes might have
either positive or negative effects on affective symptoms
and, considering antihypertensive treatment status as a
whole, cannot completely take into account the impact
of antihypertensive drug classes on affective status. A
selection bias may have also occurred due to more fre-
quent contact with healthcare services in study members
with affective symptoms.25 Indeed, they may be more
likely to be diagnosed with HT. This is apparently in con-
trast to “diagnostic overshadowing”, a process by which
physical symptoms are misattributed to mental illness in
a clinical setting.16 However, HT is often symptomless,
which implies that HT may be present long before diag-
nosis. This suggests the possibility that aware hyperten-
sives are a select group who may be more likely to visit a
doctor. Finally, we could not exclude that a common
neurological factor may lead to both a tendency to
depression/anxiety and HT as autonomic deregulation.
From the 2216 study members with at least one valid
outcome measure, 533 were excluded from analyses
because of missing covariate data. Those excluded did
not differ in frequency of self-reported HT but were
more likely to have clinically ascertained HT compared
with those included. In population studies, there is
Figure 2 Schematic overview of
the relationship between
symptoms of anxiety and
depression and hypertension.
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compelling evidence that those with affective symptoms
are more prone to be non-participants. The NSHD
cohort was established using a socially stratiﬁed sampling
frame that ensured that it was broadly representative of
the population born in England, Scotland and Wales in
1946. Since then, losses to follow-up due to death, emi-
gration, loss of contact and permanent refusal have
occurred. Despite this, at age 60–64 years, the sample
remained representative in many respects of the national
population born at a similar time.22
CONCLUSIONS AND CLINICAL IMPLICATIONS
The most interesting clinical implication of our study is
the long-term negative psychological impact of HT label-
ling. A deﬁnitive study would be to assess the long-term
implication of such a labelling effect on well-being and
quality of life, and the potential impact on cardiovascu-
lar outcomes. Our ﬁndings might also partly explain
why prior studies have produced mixed ﬁndings regard-
ing the association of HT with common mental disorder.
When considering the association between affective
symptoms and HT, potential misclassiﬁcation due to self-
report should be considered. We also observed that
patients with affective symptoms are apparently more
often diagnosed with HT due to their increased access
to healthcare. Further studies are required to conﬁrm
this observation and to investigate if this is peculiar to
diagnosis of HT or may be extended to other major dis-
eases, such as diabetes mellitus.
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